MedTrace Logo

Bepirovirsen Liver Biopsy Study

NCT07696520 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-10

No results posted yet for this study

Summary

Bepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg\<1000 IU/ml

Conditions

  • HEPATITIS B CHRONIC
  • Hepatitis B Chronic Infection

Interventions

DRUG

Bepirovirsen

Weekly Bepirovirsen treatment for 24 weeks, with loading doses

PROCEDURE

Liver biopsy

Liver biopsy as previously described

PROCEDURE

Optional Liver biopsy

An optional Liver biopsy as previously described

Sponsors & Collaborators

Principal Investigators

  • Seng Gee Prof Lim, Professor · Division of Gastroenterology & Hepatology, National University Hospital (NUH)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-12-30
Completion
2028-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07696520 on ClinicalTrials.gov